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Abstract, 199 words 
In Japan, Transcatheter aortic valve implantation (TAVI) with Edwards-SAPIEN XT 
valve started in October 2013. All institutions should undergo a proctoring period to 
perform TAVI independently. Balloon aortic valvuloplasty (BAV) as a bridge to TAVI 
during the proctoring period should be performed with caution to avoid severe aortic 
regurgitation (AR) because bailout TAVI is not possible. We present a case in which 
BAV was successfully performed as a bridge to TAVI during the proctoring period. The 
patient was an 85-year-old man with medically uncontrollable congestive heart failure 
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due to severe aortic valve stenosis. The aortic valve area was 0.60 cm2 with a left 
ventricular ejection fraction of 20%. TAVI was considered a safe but high-risk strategy 
owing to the unstable hemodynamic condition. We chose BAV as a bridge therapy to 
TAVI. The aortic annulus diameter was 25.3 mm on computed tomography scans. We 
chose a 20-mm balloon catheter to avoid BAV-induced AR. BAV was performed 
successfully without any complications. Transfemoral TAVI was performed successfully 
16 days after BAV using a 26-mm SAPIEN XT valve. The postoperative course was 
uneventful. The case demonstrated BAV as a bridge therapy to TAVI can be safely and 
effectively performed during the proctoring period.  
 
Learning Objective: 69 words 
All institutions should undergo a proctoring period to start transcatheter aortic valve 
implantation (TAVI). Balloon aortic valvuloplasty (BAV) during the proctoring period 
should be performed with caution. The present case suggests that BAV as a bridge 
therapy to TAVI can be safely performed during the proctoring period. An accurate 
measurement of aortic annulus diameter and the use of an undersized balloon catheter 





Balloon Aortic Valvuloplasty, Transcatheter Aortic Valve Implantation, Transcatheter 
Aortic Valve Replacement.  
 
Main Text 
Word Count 1392 words 
Introduction 
Staged treatment is often conducted for patients with severe aortic valve stenosis 
undergoing transcatheter aortic valve implantation (TAVI). Several studies have 
demonstrated the efficacy of balloon aortic valvuloplasty (BAV) as a bridge therapy to 
TAVI in very high-risk patients[1,2]. Compared with the past, BAV is currently conducted 
more frequently, with the introduction of TAVI[1,2]. One of the most serious 
complications after BAV is uncontrollable aortic regurgitation (AR), which often requires 
emergent surgical aortic valve replacement (SAVR) or TAVI[2–8]. In Japan, SAPIEN XT 
(Edwards Lifesciences Inc., Irvine, CA, USA) has just become commercially available at 
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limited centers in Japan. Therefore, TAVI is still in the introductory phase in most 
Japanese institutions. Before commencing TAVI, all institutions are required to undergo 
a proctoring period. Special care is required when conducting BAV as a bridge therapy 
during the proctoring period because bailout TAVI is not possible. Herein, we present a 
patient with severe symptomatic aortic valve stenosis who was successfully treated with 
BAV and percutaneous coronary intervention (PCI) to control congestive heart failure, 
followed by TAVI. The procedure was conducted during the proctoring period. 
 
Case Report 
 An 85-year-old man with mild exertional dyspnea was referred to our hospital for 
treatment of severe aortic stenosis. His brain natriuretic peptide (BNP) level was 911 
pg/mL. Transthoracic echocardiography showed a severely calcified tricuspid aortic 
valve with a peak/mean transvalvular pressure gradient of 116/70 mm Hg, and valve 
area of 0.60 cm2. Left ventricular ejection fraction was 50% and trivial mitral 
regurgitation was observed. The patient had a history of PCI of the right and left 
circumflex coronary arteries and received dual antiplatelet therapy with aspirin (100 
mg/day) and clopidogrel (75 mg/day). Coronary angiography revealed a moderate to 
 6 
 
severe stenosis in the middle portion of the right coronary artery (RCA). SAVR plus 
coronary artery bypass grafting (CABG) or PCI plus TAVI was indicated for the patient. 
The Society of Thoracic Surgeons (STS) risk score calculated for SAVR plus CABG was 
6.3%. However, the patient refused any invasive treatments, and he was discharged 
from the hospital. Therefore, medical therapy was continued in the outpatient clinic.  
 Three months later, the patient was readmitted to the hospital because of acute 
exacerbation of congestive heart failure. Transthoracic echocardiography revealed that 
the left ventricular function was significantly reduced, with an ejection fraction of 20%. 
Mild mitral regurgitation was also observed. Congestive heart failure worsened despite 
medical treatment that included intravenous administration of inotropes, diuretics, and 
vasodilators. The BNP level was elevated to 5985 pg/dL, and chest radiography showed 
severe pulmonary congestion, cardiomegaly, and bilateral pleural effusions (Figure 1A). 
The patient was deemed inoperable for SAVR plus CABG. The STS score was 12.5% at 
that time. TAVI was considered a possible but high-risk strategy owing to the unstable 
hemodynamic condition. We planned a staged procedure: first, BAV and PCI to stabilize 
the patient’s condition followed by TAVI under safer conditions. This plan required 
approval by off-site proctors because our institution was still in the proctoring period. All 
 7 
 
required data were sent to the proctors, and the plan was approved after detailed 
discussion.  
 After obtaining the approval of our institutional human ethics committee and the written 
informed consent, BAV and PCI were conducted under local anesthesia. Three 
introducer sheaths were placed: a 12-F introducer sheath in the left femoral artery, a 5-F 
introducer sheath in the right femoral artery, and a 7-F introducer sheath in the right 
femoral vein. First, we conducted right heart catheterization, which showed a mean right 
arterial pressure of 14 mm Hg, mean pulmonary arterial pressure of 36 mm Hg, and 
mean pulmonary wedge pressure of 31 mm Hg. Cardiac output, determined by using 
the Fick method, was 2.35 L/min (cardiac index = 1.49 L·min−1·m−2). A 5-F Amplatz Left 
1.0 diagnostic catheter and a 0.035-inch straight guidewire were used to cross the 
stenotic aortic valve. Simultaneous pressure tracing demonstrated a mean pressure 
gradient of 51 mm Hg across the aortic valve, and the aortic valve area was 0.32 cm2, 
as calculated by using the Gorlin formula (Figure 2A). The aortic annulus diameter was 
approximately 25 mm on computed tomography scans (Figure 3). We chose a 20-mm 
Maxi-LD balloon catheter (Cordis Corporation/Johnson & Johnson, Bridgewater, NJ, 
USA) for BAV to avoid BAV-induced AR. After placing a 0.035-inch extra-stiff guidewire 
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in the left ventricle, the balloon catheter was delivered retrogradely, and inflation was 
conducted under rapid right ventricular pacing at a heart rate of 200 bpm (Figure 2B). 
Post-BAV simultaneous pressure tracing showed that the mean pressure gradient 
decreased to 14 mm Hg and the aortic valve area increased to 0.86 cm2 (Figure 2C). 
Transthoracic echocardiography showed that the AR remained trivial. PCI for the RCA 
was subsequently performed. A 2.5-mm × 24-mm Promus premiere stent (Boston 
Scientific, USA) was implanted in the middle portion of the RCA. Both BAV and PCI 
were completed successfully without any complications.  
The patient’s symptoms and hemodynamic parameters improved significantly after 
BAV. In fact, the BNP level decreased, but remained high, at 2867 pg/mL. Chest 
radiography showed improvement of the congestive heart failure (Figure 1B). 
Transthoracic echocardiography showed that the mean/peak transvalvular pressure 
gradient decreased to 30/50 mm Hg. The left ventricular ejection fraction improved to 
25% and mild mitral regurgitation remained. Transfemoral TAVI was performed 16 days 
after BAV, under supervision of the on-site proctor. An 18-Fr e-sheath was inserted from 
the left femoral artery after surgical cut down, with the patient under general anesthesia. 
The aortic valve was crossed with a 5-F Amplatz Left 1.0 diagnostic catheter and a 
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0.035-inch straight guidewire. Pre-dilatation was conducted with a 25-mm Maxi LD 
balloon catheter (Cordis/Johnson & Jonson, USA) under rapid pacing at 200 bpm after 
placing a 0.035-inch extra-stiff guidewire in the left ventricle. Then, a 26-mm SAPIEN 
XT valve was deployed using 2 cc overfilled deployment balloon under rapid pacing at 
200 bpm. Transesophageal echocardiography demonstrated that the valve was 
implanted in the correct position with mild perivalvular leakage. The 18-F e-sheath was 
retracted, and the arteriotomy was closed. Figure 4 shows the fluoroscopic images 
during TAVI. All procedures were successfully completed, and no procedural 
complications occurred. The total procedure time from skin to skin was 110 minutes, 
and the total amount of contrast media was 90 mL.  
Congestive heart failure improved remarkably after TAVI. The BNP level decreased to 
745 pg/mL, and chest radiography showed no signs of congestive heart failure (Figure 
1C). Transthoracic echocardiography performed 8 days after TAVI showed mild 
paravalvular regurgitation, a peak/mean transvalvular pressure gradient of 12/6 mm Hg, 
a valve area of 1.1 cm2.  The left ventricular ejection fraction was 36% with trivial mitral 




This is the first case report demonstrating that BAV as a bridge therapy to TAVI can be 
safely and effectively performed during the proctoring period. BAV-induced severe AR 
was avoided with the use of a smaller balloon catheter. The valve function and 
hemodynamic status improved after BAV, which provided a better patient condition for 
TAVI.  
The indication of BAV has been limited in patients who are not good candidates for 
SAVR because restenosis almost inevitably occurs within a few months, and no clear 
survival advantage has been demonstrated[6,9]. 
However, BAV is currently used more commonly as a bridge therapy to TAVI. BAV 
provides better valve function and a more stable hemodynamic condition for a short 
period of time. Within this period, TAVI can be performed under safer conditions. 
Serious complications related to BAV include stroke, AR, cardiac tamponade, 
atrioventricular block, vascular complications, and death. When medically 
uncontrollable AR occurs after BAV, emergent surgical valve replacement or TAVI is 
required to rescue the patient. However, emergent TAVI is not an option during the 
proctoring period. BAV during the proctoring period should be performed with caution to 
avoid severe AR requiring surgical or percutaneous aortic valve replacement. Severe 
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AR after BAV is a rare but possible complication. The frequency of BAV-induced severe 
AR varies from 0 to 6%, but is approximately 1% on average[2–9]. Several studies 
recommended using smaller balloon catheter to avoid acute complications after 
BAV[7,8,10]. An accurate measurement of aortic annulus diameter with computed 
tomography and the use of an undersized balloon catheter might reduce the risk of 
BAV-related AR. In the present case, a 20-mm-diameter balloon catheter was employed 
despite an annulus diameter of 25.0 mm, and the post-BAV AR was trivial.  
In summary, we present a case of severe aortic stenosis that was successfully treated 
with BAV and staged TAVI. The results suggest that BAV as a bridge therapy to TAVI 
can be safely and effectively performed during the proctoring period, with caution.  
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Changes on chest radiographs and in the brain natriuretic peptide (BNP) level. A, A 
chest radiograph before balloon aortic valvuloplasty (BAV) showing cardiomegaly, 
bilateral pleural effusions, and pulmonary congestion. B, A chest radiograph after BAV 
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showing signs of improvement; no pleural effusion can be observed, but cardiomegaly 
and pulmonary are still present. C, The chest radiograph after transcatheter aortic valve 
implantation (TAVI) shows almost normal findings.  
Figure 2 
 
Fluoroscopic image during balloon aortic valvuloplasty (BAV) and simultaneous 
pressure tracings from the left ventricle and aorta. A, The pressure tracing before BAV 
showing a mean pressure gradient of 51 mm Hg and aortic valve area of 0.32 cm2. B, 
Balloon inflation with a 20-mm balloon catheter under rapid right ventricular pacing. C, 
The pressure tracing after BAV showing a mean pressure gradient of 14 mm Hg and 






Computed tomography scans. A, Sinotubular junction diameter was 21.9 x 25.0 mm. B, 
Valsalva diameter was 29.4 x 30.8 x 31.3. Annulus diameter was approximately 25 mm; 
the average diameter was 25.9 mm (diameter: 22.5 x 29.2), the diameter calculated 
from the perimeter was 25.3 mm (perimeter: 79.5 mm), and the diameter calculated 






Fluoroscopic images during transcatheter aortic valve implantation (TAVI). A, An 
aortogram during pre-dilatation with a 25-mm balloon catheter showing trivial aortic 
regurgitation. B, Implantation of a 26-mm SAPIEN XT valve under rapid right ventricular 
pacing. C, The final aortogram showing mild aortic regurgitation and intact coronary 
arteries.  
 
